Foley Hoag’s Government Strategies practice is active in all aspects of policymaking at the federal level. Our lawyers collaborate with our clients and the public sector to achieve mutually beneficial solutions to public policy issues. We pride ourselves on our ability to secure our clients’ strategic goals by combining a deep, substantive knowledge of issues critical to our clients’ businesses and industries with a mastery of federal legislative and regulatory processes.
-
Medicare Regulatory Attorney Jayson Slotnik Joins Foley Hoag's Life Sciences Practice
[Read More]
Publications more
- Supreme Court Decision in Citizens United v. Federal Election Commission Changes the Landscape for Corporate Funding of Election Communications [Read More]
- Justice Department Seeks Increased Funding for Fraud Prevention and Enforcement; Financial, Mortgage and Healthcare Fraud Remain Key Priorities in FY 2011 Budget [Read More]
- New Federal Earmark Rules Will Impact For-Profit Companies [Read More]
- USCIS Initiates Expanded Employer Site Visit Program [Read More]
- House Financial Services Subcommittee Releases Discussion Draft Bills of the Investor Protection Act and the Private Fund Investment Advisers Registration Act [Read More]
Client Successes more
-
Biomedical Advanced Research and Development Authority (BARDA)
In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
-
Bringing Law and Science Together
On behalf of a leading biotechnology company, our Government Strategies lawyers assembled a persuasive legal and scientific case that secured a critical federal policy decision affecting the coding and payment of important therapies for Medicare beneficiaries. [Read More]